The development of AML is induced by conditional knock-in of mutant DNMT3a in the haematopoietic system of mice, and abnormal mTOR pathway activation caused by DNMT3a mutation-mediated hypomethylation is considered a potential therapeutic target27. Here, MTOR is linked to acute myeloid leukemia.